Clinical trial
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone…
NCT00043212 · Northwest Biotherapeutics, Industry · Withdrawn
Key facts
| NCT number | NCT00043212 |
|---|---|
| Title | Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective. |
| Official title | A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating DCVax(tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | Northwest Biotherapeutics, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Dendritic cell immunotherapy |
| Enrollment | 0 |
| First posted | Aug 8, 2002 |
| Last update posted | May 1, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: